MRFR Year End Sale
Wound Care Biologics Market Research Report – Forecast to 2030

Wound Care Biologics Market Research Report: Information by Product Type (Biological Skin Substitutes, Topical Agents), Wound Type (Surgical and Traumatic Wounds, Diabetic Foot Ulcer, Pressure Ulcers), End User (Hospitals, Clinics) -Forecast till 2030

ID: MRFR/MED/5101-HCR | December 2022 | Region: Global | 100 Pages         

Wound Care Biologics Market

Wound care biologics market is projected to grow to reach USD 1.20 billion in 2017, at a CAGR of 10.50% over the forecast period

Segmentation

by Product Type Biological Skin Substitutes Topical Agents
Wound Type Surgical and Traumatic Wounds Diabetic Foot Ulcer Pressure Ulcers
End User Hospitals Clinics

Key Players

  • Integra LifeSciences Corporation (US)
  • Smith & Nephew (UK)
  • Wright Medical (US)
  • Mölnlycke Health Care AB (Sweden)
  • MiMedx Group (US)
  • Vericel Corporation (US)
  • Anika Therapeutics (US)
  • Osiris Therapeutics (US)
  • Marine Polymer Technologies

Drivers

  • increasing prevalence of chronic diseases and burn injuries
  • increasing healthcare expenditure
Speak to Analyst Request a Free Sample

Wound Care Biologics Market overview:


Over the projected period, the wound care biologics market is predicted to increase considerably. In 2017, the wound care biologics market was estimated to be worth USD 1.20 billion, and the market is expected to increase at a CAGR of 10.50% from 2022 to 2030. Wound care biologics products help the body repair wounds naturally by creating an active healing environment. Diabetic ulcers, venous ulcers, arterial ulcers, and pressure ulcers are the most common wounds treated with biologics.


The wound care biologics market is predicted to develop due to reasons such as the rising prevalence of chronic illnesses and burn injuries, as well as rising healthcare spending. According to the Centers for Disease Control and Prevention (CDC), around 2.8 million persons were admitted to hospitals owing to injuries in 2015. Over the projection period, however, the wound care biologics market will be hampered by high treatment costs, a lack of awareness, and insufficient education and training.


Segmentation


The wound care biologics market has been segmented into product type, wound type, and end user.


Based on product type, has been segmented into biological skin substitutes and topical agents. The biological skin substitutes segment is expected to account for the largest share and fastest growing segment of the market in 2017.


The market, by wound type, has been segmented into ulcers, surgical & traumatic wounds, and burns. The ulcers segment has been further segmented into diabetic foot ulcers, pressure ulcers, venous leg ulcer, and others.


The market, by end user, has been segmented into hospitals, ambulatory surgical centers, and clinics.


The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The wound care biologics market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.


The European wound care biologics market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.


The wound care biologics market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The wound care biologics market in the Middle East & Africa has been segmented into the Middle East and Africa.


Key players


Integra LifeSciences Corporation (US), Smith & Nephew (UK), Wright Medical (US), Mölnlycke Health Care AB (Sweden), MiMedx Group (US), Vericel Corporation (US), Anika Therapeutics (US), Osiris Therapeutics (US), Marine Polymer Technologies, Inc. (US), Kerecis (Iceland), Solsys Medical (US), ACell (US), and Organogenesis (US) are some of the key players in the wound care biologics market.


Regional Market Summary


Geographically, the Americas is anticipated to dominate the wound care biologics market owing to a well-developed healthcare sector, growing occurrences of chronic wounds, rising prevalence of diabetes and rising geriatric population. According to the National Diabetes Statistics Report 2017, about 30.3 million suffer from diabetes in Americans.


Europe is expected to hold the second largest position in the wound care biologics market. The market growth in this region is attributed to the increasing prevalence of diabetes and developed healthcare infrastructure.


The wound care biologics market in Asia-Pacific region consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia-Pacific. The Asia-Pacific region is expected to be the fastest growing region owing to the huge patient population of chronic diseases such as diabetes in countries such as India and China.


The Middle East & Africa has the least share of the market. Majority of the market of this region is expected to be held by the Middle East region due to a well-developed healthcare sector and growing government initiatives for the healthcare sector.


Wound Care Biologics Market, by Product Type



  • Skin Substitute

  • Human Donor Tissue

  • Acellular animal-derived

  • Biosynthetic

  • Topical Agents


Wound Care Biologics Market, by Wound Type



  • Ulcers

  • Diabetic foot ulcers

  • Venous ulcers

  • Pressure ulcers

  • Other ulcers

  • Surgical and Traumatic Wounds

  • Burns


Wound Care Biologics Market, by End User



  • Hospitals

  • Clinics

  • Other End Users


Wound Care Biologics Market, by Region



  • Americas





    • North America

    • US

    • Canada

    • South America





  • Europe





    • Western Europe

    • Germany

    • France

    • Italy

    • Spain

    • UK

    • Rest of Western Europe

    • Eastern Europe





  • Asia-Pacific





    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific





  • The Middle East & Africa





    • Middle East

    • Africa




Recent Development


Wright Medical Group Inc. manufactures human replacement components. The company creates replacement joints for the foot, ankle, hand, elbow, shoulder, and other damaged joints. The IN BONE, CLAW, and ORTHOLOC systems for foot and ankles, as well as the MICRONAIL implants for wrist fractures, are among the product lines. Wright's goods are distributed in over 60 countries, with the United States being the main market. Wright Medical Group N.V. was formed in 2015 when the company merged with Tornier of the Netherlands.


MiMedx Group Inc. is a medical equipment manufacturer. Biomaterials for soft tissue repair, such as tendons, ligaments, and cartilage, are the company's main emphasis, as well as various biomaterial-based solutions for other medical purposes. The MiMedx Group is a global provider of medical services.

Intended Audience



  • Wound Care Biologics Manufacturers and Vendors

  • Various Research and Consulting Firms

  • Wound Care Biologics Distributors

  • Hospitals



Report Scope:

Report Attribute/Metric Details
  Market Size

  • 2017: USD 1.20 Billion
  • 2030: Significant Value
  •   CAGR   10.50% (2020-2030)
      Base Year   2019
      Forecast Period   2020-2030
      Historical Data   2018
      Forecast Units   Value (USD Billion)
      Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
      Segments Covered   Product Type, Wound Type, and End User
      Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
      Key Vendors   Integra LifeSciences Corporation (US), Smith & Nephew (UK), Wright Medical (US), Mölnlycke Health Care AB (Sweden), MiMedx Group (US), Vericel Corporation (US), Anika Therapeutics (US), Osiris Therapeutics (US), Marine Polymer Technologies, Inc. (US), Kerecis (Iceland), Solsys Medical (US), ACell (US), and Organogenesis (US)
      Key Market Opportunities   New product launches and R&D Amongst major key Players
      Key Market Drivers

  • Increasing prevalence of chronic diseases and burn injuries
  • Increasing healthcare expenditure


  • Speak to Analyst Ask for Customization